Cape Investment Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$89.9K Buy
+181
New +$80.2K 0.02% 365
2026
Q1
Sell
-115
Closed -$52.1K 1194
2025
Q4
$52.1K Buy
115
+55
+92% +$23.7K 0.02% 406
2025
Q3
$23.5K Buy
60
+16
+36% +$6.69K 0.02% 303
2025
Q2
$19.6K Sell
44
-3
-6% -$1.38K 0.01% 511
2025
Q1
$22.8K Sell
47
-1
-2% -$466 0.01% 455
2024
Q4
$19.3K Buy
48
+18
+60% +$8.34K 0.01% 485
2024
Q3
$14K Sell
30
-1
-3% -$480 0.01% 510
2024
Q2
$14.5K Hold
31
0.01% 470
2024
Q1
$13K Sell
31
-225
-88% -$95.1K 0.01% 499
2023
Q4
$104K Buy
256
+215
+524% +$79.4K 0.05% 215
2023
Q3
$14.3K Hold
41
0.01% 504
2023
Q2
$14.4K Hold
41
0.01% 491
2023
Q1
$12.9K Buy
+41
New +$12.3K 0.01% 497

Other funds holding VRTX

Cape Investment Advisory's VRTX Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 181 shares worth $89.9K. The stake represents 0.02% of the portfolio and ranks #365 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in VRTX as recently as Q4 2025.

Cape Investment Advisory first reported a position in VRTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $104K in Q4 2023. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Cape Investment Advisory held 181 shares of Vertex Pharmaceuticals worth $89.9K as of Q2 2026.
  • Vertex Pharmaceuticals was a new Cape Investment Advisory position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.02% of Cape Investment Advisory's portfolio in Q2 2026, its #365 holding.
  • Cape Investment Advisory first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Cape Investment Advisory's Vertex Pharmaceuticals position peaked at $104K in Q4 2023.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.